直肠癌患者MRI黏液量与全程新辅助治疗后结局的关系
该回顾性单中心研究纳入2018年1月至2019年12月接受全程新辅助治疗后手术或非手术管理的189例直肠腺癌患者,由两名腹部放射科医师独立对基线和再分期MRI的肿瘤或瘤床黏液量进行评分,采用<50% vs ≥50%和無黏液 vs 任何黏液两种分类。结果显示不同黏液量的肿瘤在病理完全缓解/持续临床完全缓解率、局部复发/局部再生时间、远处复发时间和无病生存方面均无显著差异。作者结论认为,在没有其他高危特征时,再分期MRI上的黏液不应排除非手术管理或促使更激进治疗。
要点
- 再分期MRI显示黏液时,若无其他高危特征,不应据此排除非手术管理或加码治疗。
- 基线MRI仅15%(29/189)肿瘤含任何黏液,再分期MRI仅14%(27/189)含任何黏液。
- 不同黏液量肿瘤的病理完全缓解/持续临床完全缓解率、局部复发/再生时间、远处复发时间和无病生存均无显著差异。
核心结论
- 再分期MRI上的黏液在没有其他高危特征时不应排除非手术管理或促使更激进治疗,不同黏液量肿瘤的多种结局无显著差异。
研究设计与样本
- 回顾性单中心研究,纳入2018年1月至2019年12月接受全程新辅助治疗后手术或非手术管理的189例直肠腺癌患者,两名腹部放射科医师独立对基线和再分期MRI的肿瘤或瘤床黏液量进行评分。
关键影像表现/征象
- 基线MRI上29/189(15%)患者肿瘤含任何量黏液,再分期MRI上27/189(14%)患者肿瘤含任何黏液。
- 103/189(54%)患者在全程新辅助治疗后接受手术,86/189(46%)接受非手术管理。
- 59/189(31%)患者出现局部复发、远处复发或局部再生。
诊断标准与关键数值
- 黏液量采用两种分类评分:<50% vs ≥50%(类似组织学分类)和無黏液 vs 任何黏液。
- 不同黏液量肿瘤在病理完全缓解/持续临床完全缓解率、局部复发/局部再生时间、远处复发时间和无病生存方面均无显著差异,无论黏液量判定时机和标准(基线MRI、再分期MRI和组织病理学的<50% vs ≥50%标准及無 vs 任何黏液标准)。
临床应用与阅片要点
- 作者结论认为,再分期MRI上的黏液在没有其他高危特征时不应排除非手术管理或促使更激进治疗。
- 基线MRI和再分期MRI上肿瘤含任何黏液的比例分别为15%(29/189)和14%(27/189)。
- 不同黏液量肿瘤的病理完全缓解/持续临床完全缓解率、局部复发/局部再生时间、远处复发时间和无病生存均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the relationship between mucin quantity on MRI and outcomes following total neoadjuvant therapy (TNT) in patients with rectal cancer.
MATERIALS AND METHODS: This retrospective, single-center study included patients with rectal adenocarcinoma who underwent TNT followed by surgery or non-operative management (NOM) from January 2018-December 2019. Two abdominal radiologists independently scored baseline and restaging MRIs for mucin quantity in the tumor or tumor bed, using two classifications: < 50% vs. ≥ 50% (similar to histological classification) and no mucin vs. any mucin. Statistical analysis was performed to determine if patient outcomes differed between tumors of different mucin quantities.
RESULTS: Among 189 patients, 114/189 (60%) male, 75/189 (40%) female), the median age at diagnosis was 57 years (IQR: 48-68). On baseline MRI, 29/189 (15%) patients had tumor containing any amount of mucin, and on restaging MRI, 27/189 (14%) patients had tumor containing any mucin. 103/189 (54%) underwent surgery after TNT, and 86/189 (46%) underwent NOM. 59/189 (31%) experienced local recurrence, distant recurrence, or local regrowth. There were no significant differences in the rate of pathologic complete response/sustained clinical complete response, time to local recurrence/local regrowth, time to distant recurrence, and disease-free survival between tumors of different mucin quantity, regardless of the timing and criteria for determining mucin quantity (< 50% vs. ≥ 50% mucin criteria, and no vs. any mucin criteria on baseline MRI, restaging MRI and on histopathology, respectively).
CONCLUSION: Mucin on restaging MRI should not rule out NOM or prompt more aggressive therapy in the absence of other high-risk features.
KEY POINTS: Question Is there a correlation in mucin content of tumor and patient outcomes in the setting of total neoadjuvant therapy followed by surgery or nonoperative management? Finding There were no prognostic differences between tumors of different mucin quantity in multiple outcomes, including local recurrence, local regrowth, recurrence, and disease-free survival. Clinical relevance Although prior studies have shown conflicting results, our findings suggest mucin content on MRI may not predict worse outcomes in rectal cancer patients treated with contemporary total neoadjuvant therapy, including those managed nonoperatively.
引用
- Javed-Tayyab S, Miranda J, Reif de Paula T, et al. Mucin quantity on MRI and outcomes following total neoadjuvant therapy in patients with rectal cancer. Eur Radiol. 2025. PMID: 40856737. doi:10.1007/s00330-025-11967-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。